Occurrence of Ischemic Stroke in Patients With Atrial Fibrillation Receiving Non-Vitamin K Oral Anticoagulants: Causes and Prevention Strategies

키워드

참고문헌 (72)

1. Connolly SJ, "Dabigatran versus warfarin in patients with atrial fibrillation", N Engl J Med, 361, pp.1139~1151 (2009)
2. Patel MR, "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation", N Engl J Med, 365, pp.883~891 (2011)
3. Granger CB, "Apixaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 365, pp.981~992 (2011)
4. Giugliano RP, "Edoxaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 369, pp.2093~2104 (2013)
5. Hindricks G, "2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery(EACTS) : the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology(ESC)developed with the special contribution of the European Heart Rhythm Association(EHRA)of the ESC", Eur Heart J, 42, pp.373~498 (2021)
6. January CT, "2019 AHA", ACC, ACC, pp.HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology, American Heart Association Task Force on clinical practice guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons[DOI]
7. Tanaka K, "Atrial fibrillation-associated ischemic stroke patients with prior anticoagulation have higher risk for recurrent stroke", Stroke, 51, pp.1150~1157 (2020)
8. Yaghi S, "Ischaemic stroke on anticoagulation therapy and early recurrence in acute cardioembolic stroke : the IAC study", J Neurol Neurosurg Psychiatry, 92, pp.1062~1067 (2021)
9. Seiffge DJ, "Ischemic stroke despite oral anticoagulant therapy in patients with atrial fibrillation", Ann Neurol, 87, pp.677~687 (2020)
10. Auer E, "Stroke severity in patients with preceding direct oral anticoagulant therapy as compared to vitamin K antagonists", J Neurol, 266, pp.2263~2272 (2019)
11. Grymonprez M, "Worldwide trends in oral anticoagulant use in patients with atrial fibrillation from 2010 to 2018 : a systematic review and meta-analysis", Europace, 24, pp.887~898 (2022)
12. Yu Z, "Trends of ambulatory oral anticoagulant prescription in five major cities of China, 2012-2017", BMC Health Serv Res, 20, pp.209~ (2020)
13. Oh Young Bang, "Asian Patients with Stroke plus Atrial Fibrillation and the Dose of Non-Vitamin K Oral Anticoagulants", 대한뇌졸중영문학회지, 18(2), pp.169~178 (2016), 대한뇌졸중학회
14. Paciaroni M, "Recurrent ischemic stroke and bleeding in patients with atrial fibrillation who suffered an acute stroke while on treatment with nonvitamin K antagonist oral anticoagulants : the RENO-EXTEND study", Stroke, 53, pp.2620~2627 (2022)
15. Jong S. Kim, "Apixaban for Secondary Stroke Prevention: Coexistant Cerebral Atherosclerosis May Increase Recurrent Strokes", 대한뇌졸중영문학회지, 24(1), pp.118~127 (2022), 대한뇌졸중학회[DOI]
16. Kim SJ, "Is atrial fibrillation always a culprit of stroke in patients with atrial fibrillation plus stroke?", Cerebrovasc Dis, 36, pp.373~382 (2013)
17. Paciaroni M, "Causes and risk factors of cerebral ischemic events in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants for stroke prevention", Stroke, 50, pp.2168~2174 (2019)
18. Jeong WK, "Volume and morphology of left atrial appendage as determinants of stroke subtype in patients with atrial fibrillation", Heart Rhythm, 13, pp.820~827 (2016)
19. Yao X, "Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation", J Am Heart Assoc, 5, pp.e003074~ (2016)
20. Gabet A, "Stroke incidence and death in atrial fibrillation patients newly treated with direct oral anticoagulants", Clin Epidemiol, 13, pp.131~140 (2021)
21. Weitz JI, "Urgent need to measure effects of direct oral anticoagulants", Circulation, 134, pp.186~188 (2016)
22. Kajy M, "Treatment failures of direct oral anticoagulants", Am J Ther, 28, pp.e87~e95 (2021)
23. Steinberg BA, "Frequency and outcomes of reduced dose non-vitamin K antagonist anticoagulants : results from ORBIT-AF II(the outcomes registry for better informed treatment of atrial fibrillation II)", J Am Heart Assoc, 7, pp.e007633~ (2018)
24. Wang KL, "Non–vitamin K antagonist oral anticoagulants for stroke prevention in Asian patients with nonvalvular atrial fibrillation : meta-analysis", Stroke, 46, pp.2555~2561 (2015)
25. Heidbuchel H, "Updated European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation", Europace, 17, pp.1467~1507 (2015)
26. Lin SY, "Factors for recurrent stroke among Asian patients with non-valvular atrial fibrillation under non-vitamin K antagonist oral anticoagulant therapy", J Formos Med Assoc, 119, pp.1799~1806 (2020)
27. Avezum A, "Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease : findings from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation(ARISTOTLE)trial", Circulation, 132, pp.624~632 (2015)
28. Ezekowitz MD, "Comparison of dabigatran and warfarin in patients with atrial fibrillation and valvular heart disease : the RE-LY trial(Randomized Evaluation of Long-Term Anticoagulant Therapy)", Circulation, 134, pp.589~598 (2016)
29. Connolly SJ, "Rivaroxaban in rheumatic heart disease-associated atrial fibrillation", N Engl J Med, 387, pp.978~988 (2022)
30. Deitelzweig S, "Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients with active cancer", JACC CardioOncol, 3, pp.411~424 (2021)
31. Chan YH, "Clinical outcomes in atrial fibrillation patients with a history of cancer treated with non-vitamin K antagonist oral anticoagulants : a nationwide cohort study", Stroke, 52, pp.3132~3141 (2021)
32. Ordi-Ros J, "Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome : a randomized noninferiority trial", Ann Intern Med, 171, pp.685~694 (2019)
33. Khairani CD, "Direct oral anticoagulants vs vitamin-K antagonists in thrombotic antiphospholipid syndrome : meta-analysis of randomized controlled trials", J Am Coll Cardiol (2022)[DOI]
34. Polymeris AA, "Aetiology, secondary prevention strategies and outcomes of ischaemic stroke despite oral anticoagulant therapy in patients with atrial fibrillation", J Neurol Neurosurg Psychiatry, 93, pp.588~598 (2022)
35. Ay H, "Admission international normalized ratio and acute infarct volume in ischemic stroke", Ann Neurol, 64, pp.499~506 (2008)
36. Macha K, "Cerebral ischemia in patients on direct oral anticoagulants", Stroke, 50, pp.873~879 (2019)
37. Xian Y, "Association of preceding antithrombotic treatment with acute ischemic stroke severity and in-hospital outcomes among patients with atrial fibrillation", JAMA, 317, pp.1057~1067 (2017)
38. Rohla M, "Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation : the prospective, multicentre observational PREvention oF thromboembolic events-European Registry in Atrial Fibrillation(PREFER in AF)", BMJ Open, 9, pp.e022478~ (2019)
39. Budnik M, "Risk of left atrial appendage thrombus in patients with atrial fibrillation and chronic kidney disease", Cardiol J, 29, pp.205~215 (2022)
40. Michalska A, "Does the CHA2DS2-VASc scale sufficiently predict the risk of left atrial appendage thrombus in patients with diagnosed atrial fibrillation treated with non-vitamin K oral anticoagulants?", Medicine(Baltimore), 99, pp.e20570~ (2020)
41. Shah M, "Predictors of left atrial appendage thrombus despite NOAC use in nonvalvular atrial fibrillation and flutter", Int J Cardiol, 317, pp.86~90 (2020)
42. Durmaz E, "Left atrial thrombus in patients with atrial fibrillation and under oral anticoagulant therapy; 3-D transesophageal echocardiographic study", Int J Cardiovasc Imaging, 36, pp.1097~1103 (2020)
43. Gawałko M, "Decreased left atrial appendage emptying velocity as a link between atrial fibrillation type, heart failure and older age and the risk of left atrial thrombus in atrial fibrillation", Int J Clin Pract, 74, pp.e13609~ (2020)
44. Yamamoto M, "Complex left atrial appendage morphology and left atrial appendage thrombus formation in patients with atrial fibrillation", Circ Cardiovasc Imaging, 7, pp.337~343 (2014)
45. Fastner C, "Treatment standards for direct oral anticoagulants in patients with acute ischemic stroke and non-valvular atrial fibrillation : a survey among German stroke units", PLoS One, 17, pp.e0264122~ (2022)
46. Sun H, "Dabigatran as an alternative for atrial thrombosis resistant to rivaroxaban : a case report", Medicine(Baltimore), 97, pp.e13623~ (2018)
47. Watanabe T, "Dabigatran therapy resulting in the resolution of rivaroxaban-resistant left atrial appendage thrombi in patients with atrial fibrillation", Intern Med, 56, pp.1977~1980 (2017)
48. Tokunaga K, "Prior anticoagulation and short–or long–term clinical outcomes in ischemic stroke or transient ischemic attack patients with nonvalvular atrial fibrillation", J Am Heart Assoc, 8, pp.e010593~ (2019)
49. Park YK, "Genetic and non-genetic factors affecting the quality of anticoagulation control and vascular events in atrial fibrillation", J Stroke Cerebrovasc Dis, 26, pp.1383~1390 (2017)
50. Mocini D, "ANMCO position paper ‘appropriateness of prescribing direct oral anticoagulants in stroke and systemic thromboembolism prevention in adult patients with non-valvular atrial fibrillation’", Eur Heart J Suppl, 24(Suppl C), pp.C278~C288 (2022)
51. Blackshear JL, "Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation", Ann Thorac Surg, 61, pp.755~759 (1996)
52. Mahajan R, "Importance of the underlying substrate in determining thrombus location in atrial fibrillation : implications for left atrial appendage closure", Heart, 98, pp.1120~1126 (2012)
53. Sievert H, "Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation : early clinical experience", Circulation, 105, pp.1887~1889 (2002)
54. Glikson M, "EHRA", EAPCI expert consensus statement on catheter-based left atrial appendage occlusion-an update, 2020, pp.15, 1133~1180
55. Holmes DR, "Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation : a randomised non-inferiority trial", Lancet, 374, pp.534~542 (2009)
56. Holmes DR Jr, "Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy : the PREVAIL trial", J Am Coll Cardiol, 64, pp.1~12 (2014)
57. Boersma LV, "Implant success and safety of left atrial appendage closure with the WATCHMAN device : peri-procedural outcomes from the EWOLUTION registry", Eur Heart J, 37, pp.2465~2474 (2016)
58. Reddy VY, "Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation : the ASAP study(ASA plavix feasibility study with Watchman left atrial appendage closure technology)", J Am Coll Cardiol, 61, pp.2551~2556 (2013)
59. Kar S, "Primary outcome evaluation of a next-generation left atrial appendage closure device : results from the PINNACLE FLX trial", Circulation, 143, pp.1754~1762 (2021)
60. Lakkireddy D, "Amplatzer amulet left atrial appendage occluder versus Watchman device for stroke prophylaxis (Amulet IDE): a randomized, controlled trial", Circulation, 144, pp.1543~1552 (2021)
61. Osmancik P, "Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation", J Am Coll Cardiol, 75, pp.3122~3135 (2020)
62. Wilber D, "Outcomes of adjunctive left atrial appendage ligation utilizing the LARIAT compared to pulmonary vein antral isolation alone: the aMAZE trial", American Heart Association’s Scientific Sessions (AHA) (2021)
63. Fauchier L, "Device-related thrombosis after percutaneous left atrial appendage occlusion for atrial fibrillation", J Am Coll Cardiol, 71, pp.1528~1536 (2018)
64. Holmes DR Jr, "Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation : a patient-level meta-analysis", J Am Coll Cardiol, 65, pp.2614~2623 (2015)
65. Galloo X, "Left atrial appendage occlusion in recurrent ischaemic stroke, a multicentre experience", Acta Clin Belg, 77, pp.255~260 (2022)
66. Katz ES, "Surgical left atrial appendage ligation is frequently incomplete : a transesophageal echocardiograhic study", J Am Coll Cardiol, 36, pp.468~471 (2000)
67. Kanderian AS, "Success of surgical left atrial appendage closure : assessment by transesophageal echocardiography", J Am Coll Cardiol, 52, pp.924~929 (2008)
68. Ellis CR, "Angiographic efficacy of the Atriclip left atrial appendage exclusion device placed by minimally invasive thoracoscopic approach", JACC Clin Electrophysiol, 3, pp.1356~1365 (2017)
69. Toale C, "Outcomes of left atrial appendage occlusion using the AtriClip device : a systematic review", Interact Cardiovasc Thorac Surg, 29, pp.655~662 (2019)
70. Caliskan E, "Epicardial left atrial appendage AtriClip occlusion reduces the incidence of stroke in patients with atrial fibrillation undergoing cardiac surgery", Europace, 20, pp.e105~e114 (2018)
71. Kim JY, "Long-term efficacy and anticoagulation strategy of left atrial appendage occlusion during total thoracoscopic ablation of atrial fibrillation to prevent ischemic stroke", Front Cardiovasc Med, 9, pp.853299~ (2022)
72. Whitlock RP, "Left atrial appendage occlusion during cardiac surgery to prevent stroke", N Engl J Med, 384, pp.2081~2091 (2021)